High-Level Overview
ABH Optics ApS is a Danish technology company developing meta-optics eyeglass lenses that are up to 90% thinner and lighter than traditional lenses, targeting the 13% of wearers with high prescriptions exceeding +/-4 diopters (up to +/-20 diopters).[1][2][3][4] These ultra-thin (1.8 mm), lightweight (3g), customizable, and environmentally friendly lenses solve longstanding issues like discomfort, heaviness, nose marks, and aesthetic drawbacks in the $40-43 billion global eyeglass lens market, which has seen little innovation for centuries.[1][3][4][5] Founded in 2022 as a DTU spin-off, the company secured €1 million pre-seed funding from High-Tech Gründerfonds (HTGF) in 2024 and €2.5 million in soft funding from EIC and others, with plans for a €4 million seed round to launch in 2026 and project €160 million in revenues by 2030.[2][3][5]
Origin Story
ABH Optics emerged from research at DTU Health Tech, leveraging an exclusive IP license from the Technical University of Denmark (DTU) and prior funding from DTU, Innovation Fund Denmark, and the EU.[1][3] The company was founded in 2022 by Anders Kristensen, Bo Svarrer Hansen (CEO), and Henrik Bense-Petersen, experts in nanotechnology and optics, to commercialize cutting-edge laser writing (100,000 dpi resolution) and meta-optics originally developed for applications like infrared lenses and lab-on-a-chip.[1][2][3] Early milestones include prototype development, nano-imprint technology, IP securing (US patent granted, two pending), and B2B explorations in optical filters for diagnostics and smartphones, building toward B2C sales to opticians and end-users.[1][5]
Core Differentiators
- Meta-Optics Technology: Shifts lens power from curvature to nanoscale surface coatings via proprietary nanotechnology, enabling 1.8 mm thickness for all powers (vs. 5.9+ mm ordinary), ultra-lightweight design (3g vs. 30g+), and easy customization for optical power and defects without altering optician workflows or materials.[1][3][4][5]
- Sustainability and Accessibility: Reduces plastic usage for eco-friendliness; matches market pricing despite innovation; allows free frame choice and aesthetic appeal.[3][4][5]
- Precision and Scalability: Handles extreme prescriptions (+/-20 diopters); backed by high-resolution laser writing; roadmap includes MVP testing, small-scale production, and panel trials.[1][2]
- IP and Funding Strength: Exclusive DTU license, patents, and €3.5M+ total funding position it as the first meta-optics prescription lens maker.[1][3][5]
Role in the Broader Tech Landscape
ABH Optics rides the surging demand for high-myopia solutions amid a global rise in vision impairments, projected to affect one billion people needing high-power lenses by 2050, fueled by aging populations and screen time.[4][5] Timing aligns with advances in nanotechnology and meta-materials, disrupting a stagnant lens industry while advancing B2B uses like smartphone optics and diagnostics.[1] Market forces favoring sustainability (plastic reduction) and personalization (custom coatings) work in its favor, potentially capturing share in the €43 billion market through cost parity and superior comfort.[3][5] As a DTU spin-off, it influences Denmark's health tech ecosystem by bridging academia to commercialization, inspiring similar IP-driven optics innovations.[1][3]
Quick Take & Future Outlook
ABH Optics is primed for market entry with 2026 launch post-€4 million seed, scaling to small production, optician sales, and €160 million revenues by 2030 via meta-optics dominance.[5] Trends like AI-driven personalization, sustainable materials, and AR/VR optics will amplify growth, potentially expanding to B2B filters and global leadership.[1][5] Its influence may evolve from niche high-prescription disruptor to industry standard-setter, transforming eyewear comfort for billions—echoing its origin as research-born innovation now ready to redefine an ancient problem.[1][4]